"Antibodies, Neutralizing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
| Descriptor ID |
D057134
|
| MeSH Number(s) |
D12.776.124.486.485.114.244 D12.776.124.790.651.114.244 D12.776.377.715.548.114.244
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neutralizing".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neutralizing".
This graph shows the total number of publications written about "Antibodies, Neutralizing" by people in this website by year, and whether "Antibodies, Neutralizing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 5 | 7 |
| 2011 | 2 | 6 | 8 |
| 2012 | 6 | 6 | 12 |
| 2013 | 4 | 8 | 12 |
| 2014 | 7 | 10 | 17 |
| 2015 | 11 | 4 | 15 |
| 2016 | 11 | 13 | 24 |
| 2017 | 9 | 13 | 22 |
| 2018 | 16 | 10 | 26 |
| 2019 | 12 | 6 | 18 |
| 2020 | 18 | 17 | 35 |
| 2021 | 19 | 22 | 41 |
| 2022 | 6 | 41 | 47 |
| 2023 | 2 | 35 | 37 |
| 2024 | 13 | 12 | 25 |
| 2025 | 7 | 21 | 28 |
| 2026 | 7 | 5 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial. Pediatrics. 2026 Jun 01; 157(6).
-
Human antibody targeting Crimean-Congo hemorrhagic fever virus glycoprotein 38 protects mice against heterologous virus challenge. J Clin Invest. 2026 May 15; 136(10).
-
A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples. J Infect Dis. 2026 Mar 17; 233(3):e646-e650.
-
Epitope-focused discovery of SARS-CoV-2 antibodies that potently neutralize Omicron variants. Nat Microbiol. 2026 Apr; 11(4):1113-1132.
-
Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: the REAL-HLH study. Blood Adv. 2026 Mar 10; 10(5):1564-1575.
-
The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults. Vaccine. 2026 Apr 02; 77:128358.
-
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials. Vaccine. 2026 Apr 02; 77:128380.
-
Structural basis for recognition of Rift Valley fever virus Gn protein by a human neutralizing monoclonal antibody with a kappa light chain. PLoS Pathog. 2026 Feb; 22(2):e1013926.
-
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances. Vaccine. 2026 Mar 19; 76:128348.
-
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab. Clin Infect Dis. 2026 Jan 16; 81(Supplement_3):i13-i16.